Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trialSalah‐Eddin Al‐Batran, Andrea Tannapfel, Ralf‐Dieter Hofheinz et al.|The Lancet Oncology|2016Cited by 738
Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study groupDominik Paul Modest, Anke Reinacher‐Schick, Ingrid Ricard et al.|Annals of Oncology|2016Cited by 344
<i>TFAP2E–DKK4</i> and Chemoresistance in Colorectal CancerMatthias Ebert, Roland M. Schmid, Marc Tänzer et al.|New England Journal of Medicine|2012Cited by 184
Expression of p73 and Its Relation to Histopathology and Prognosis in Hepatocellular CarcinomaAndrea Tannapfel, Christian Wittekind, Kurt Engeland et al.|JNCI Journal of the National Cancer Institute|1999Cited by 162
INK4a-ARF alterations and p53 mutations in hepatocellular carcinomasAndrea Tannapfel, Christian Wittekind, Claudia Busse et al.|Oncogene|2001Cited by 132